Rock Springs Capital advisory activities include management services to security portfolios and portfolio management for businesses or institutional clients.
Their exits include BeiGene, Invitae, Galera Therapeutics, Spark Therapeutics, Adaptive Biotechnologies, Ra Pharmaceuticals, AveXis, Menlo Therapeutics, Kaleido BioSciences, ZAI Lab, Ardelyx and Synlogic.
Rock Springs Capital has raised a total of $1.5 billion across 2 funds, their latest being Rock Springs Capital Fund. This fund was announced on October 5, 2017 and raised a total of $1.1 billion. They announced their Rock Springs Capital Offshore Fund on September 11, 2017 with a raised total of $395.9 million.